MSI-H

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

Retrieved on: 
星期二, 十一月 15, 2022
CPI, Hereditary nonpolyposis colorectal cancer, Science Translational Medicine, MVA, Modified vaccinia Ankara, Cancer, Peptide, Immunotherapy, Neoplasm, Population, GENESIS, MD Anderson Cancer Center, University, FSP, ASCO, Bristol Myers Squibb, Department, GE, Affirmative action, MSI-H, Patient, DNA, CD8, CRC, Myeloproliferative neoplasm, Immune system, Pembrolizumab, Gad, Janssen Pharmaceuticals, Development, Pharmaceutical industry, Vaccine, Science, EU

NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of Mismatch Repair/Microsatellite Instable High (dMMR/MSI-H) unresectable or metastatic gastric, colorectal and gastro-esophageal junction tumors.

Key Points: 
  • NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of Mismatch Repair/Microsatellite Instable High (dMMR/MSI-H) unresectable or metastatic gastric, colorectal and gastro-esophageal junction tumors.
  • Dr Marina Udier, Chief Executive Officer of Nouscom, added: "The initiation of the Phase 2 study is another significant milestone this year for our company.
  • Adenoviral Based-Vaccine Promotes Neoantigen Specific CD8+ T Cell Stemness And Tumor Rejection, Science Translational Medicine; 14, 657, 2022
    NOUS-209 is an off-the-shelf cancer immunotherapy for Microsatellite Instable High (MSI-H) tumors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

Retrieved on: 
星期二, 十一月 15, 2022
CPI, Hereditary nonpolyposis colorectal cancer, Science Translational Medicine, MVA, Modified vaccinia Ankara, Cancer, Peptide, Immunotherapy, Neoplasm, Population, GENESIS, MD Anderson Cancer Center, University, FSP, ASCO, Bristol Myers Squibb, Department, GE, Affirmative action, MSI-H, Patient, DNA, CD8, CRC, Myeloproliferative neoplasm, Immune system, Pembrolizumab, Gad, Janssen Pharmaceuticals, Development, Pharmaceutical industry, Vaccine, Science, EU

NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of Mismatch Repair/Microsatellite Instable High (dMMR/MSI-H) unresectable or metastatic gastric, colorectal and gastro-esophageal junction tumors.

Key Points: 
  • NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of Mismatch Repair/Microsatellite Instable High (dMMR/MSI-H) unresectable or metastatic gastric, colorectal and gastro-esophageal junction tumors.
  • Dr Marina Udier, Chief Executive Officer of Nouscom, added: "The initiation of the Phase 2 study is another significant milestone this year for our company.
  • Adenoviral Based-Vaccine Promotes Neoantigen Specific CD8+ T Cell Stemness And Tumor Rejection, Science Translational Medicine; 14, 657, 2022
    NOUS-209 is an off-the-shelf cancer immunotherapy for Microsatellite Instable High (MSI-H) tumors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Doctor of Philosophy, Patient, Neoplasm, Immune tolerance, Research, Sumathi Best Television Current Reporting Award, MSI-H, Therapy, Growth, Maintenance, SAN, PLOS, PLOS Genetics, Genetics, GLOBE, Squamous cell carcinoma, Safety, Pharmacokinetics, Securities Exchange Act of 1934, Poster, Terminology, Nature Genetics, Immunotherapy, Securities Act of 1933, 23andMe, Annual general meeting, Annual report, U.S. Securities and Exchange Commission, Cancer, Genome, Helios Techno Holding Co., Ltd., Security (finance), Society, CD200, SITC, MD, Nature, Myelocyte, Primary peritoneal carcinoma, Pharmaceutical industry, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • 23andMe has more than 13 million genotyped customers, over 80% of whom consent to participate in research.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.
  • Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

Retrieved on: 
星期一, 九月 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Strathcona County, EGFR, HIV disease progression rates, Brentuximab vedotin, Hodgkin lymphoma, Cancer, UC, Bristol Myers Squibb, CHL, Research, HCC, Survival, RCC, Large-cell lung carcinoma, ALK, Life, Squamous cell carcinoma, Head, Recurrence, Incidence, Adrenocorticotropic hormone, Administration, Nivolumab, Irinotecan, Infection, Ipilimumab, ACTH, Neck, SCCHN, Hepatocellular carcinoma, Diagnosis, Science, Sorafenib, Pneumonitis, Lymph, Patient, Fourth grade, FDA, NSCLC, Oxaliplatin, Adult, Neoplasm, MSI-H, CRC, HSCT, PD-L1, Melanoma, Creatinine, ESCC, Degenerative disease, Prednisone, Pharmaceutical industry, Medical imaging, Vaccine, Platinum

Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Key Points: 
  • Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
  • In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

Retrieved on: 
星期四, 八月 11, 2022
FDA, Adenoviridae, Association, ASCO, American Association, MSI-H, Neoplasm, Institute, Patient, German Resource Center for Genome Research, Cancer, Vaccine, Tumor microenvironment, AACR, Phenotype, Lead, Science Translational Medicine, US, American Association for Cancer Research, Veteran, LinkedIn, Colorectal cancer, Medical imaging, Pharmaceutical industry

BASEL, Switzerland, Aug. 11, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announces the publication in Science Translational Medicine of preclinical and clinical research describing a novel mechanism of action driven by its viral vector-based vaccine platform encoding tumor neoantigens.

Key Points: 
  • These T cells were shown to exhibit astem-like phenotype capable of infiltrating the tumor microenvironment and evolving into effector-memory CD8+ T cells.
  • This mechanism has been validated in both preclinical studies and observed in patients and furthers our understanding of the clinical potential of adenoviral based cancer vaccines.
  • Nouscom's proprietary platform harnesses the full power of the immune response by designing viral vectored vaccines based on multiple neoantigens and other immunomodulators.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

Retrieved on: 
星期四, 八月 11, 2022
FDA, Adenoviridae, Association, ASCO, American Association, MSI-H, Neoplasm, Institute, Patient, German Resource Center for Genome Research, Cancer, Vaccine, Tumor microenvironment, AACR, Phenotype, Lead, Science Translational Medicine, US, American Association for Cancer Research, Veteran, LinkedIn, Colorectal cancer, Medical imaging, Pharmaceutical industry

BASEL, Switzerland, Aug. 11, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announces the publication in Science Translational Medicine of preclinical and clinical research describing a novel mechanism of action driven by its viral vector-based vaccine platform encoding tumor neoantigens.

Key Points: 
  • These T cells were shown to exhibit astem-like phenotype capable of infiltrating the tumor microenvironment and evolving into effector-memory CD8+ T cells.
  • This mechanism has been validated in both preclinical studies and observed in patients and furthers our understanding of the clinical potential of adenoviral based cancer vaccines.
  • Nouscom's proprietary platform harnesses the full power of the immune response by designing viral vectored vaccines based on multiple neoantigens and other immunomodulators.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn

Roche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA

Retrieved on: 
星期四, 八月 11, 2022
MSD, Endometrial cancer, Death, Cancer, Prevalence, Hoffmann-La Roche, Patient, Pembrolizumab, Immunohistochemistry, DNA, US Foods, Food, Disease, Merck Sharp & Dohme Federal Credit Union, HIV disease progression rates, DNA mismatch repair, List of Hindawi academic journals, MSI-H, Pharma, Merck, Colorectal cancer, Merck & Co., PMMR 62, MMR, European Commission, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Benchmark, Internet, DNA replication, PD-1, Cell, IHC, Radiation, Roche Diagnostics, RO, TKI, Food and Drug Administration, ROG, FDA, Woman, Biomarker, Genentech, Adult, Dow Jones, Neoplasm, Protein, Medical imaging, Pharmaceutical industry, Vaccine, Fine chemical, Pathology, Chugai Pharmaceutical Co., Diagnosis

Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps identify solid tumour patients, including endometrial cancer patients, for treatment with Merck's immunotherapy KEYTRUDA.

Key Points: 
  • Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps identify solid tumour patients, including endometrial cancer patients, for treatment with Merck's immunotherapy KEYTRUDA.
  • "Roche is committed to advancing personalised healthcare options for all solid tumour patients," said Jill German, Head of Pathology, Roche Diagnostics.
  • For endometrial cancer patients without this MMR deficiency (pMMR) PD-1 inhibitors may retain activity when combined with a tyrosine kinase inhibitor (TKI).
  • FDA approval of the label expansion for the VENTANA MMR RxDx Panel provides clinicians with access to a fully automated panel of MMR biomarkers tested by IHC.

Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
星期一, 六月 6, 2022
SD, Oncology, Immunotherapy, Veteran, FSP, GE, US, Society, Modified vaccinia Ankara, AACR, Neoplasm, LinkedIn, MVA, ASCO, Hope, Annual general meeting, Primary health centre, Pembrolizumab, City, American Association, MSI, American Society of Clinical Oncology, MSI-H, Patient, GENESIS, Gad, FDA, DNA, Tumor microenvironment, Trial of the century, Microsatellite instability, Association, Cancer, ELISpot, American Association for Cancer Research, Peptide, Safety, Vaccine, Pharmaceutical industry, Medical imaging

BASEL, Switzerland, June 6, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced first data from the completed Phase 1 trial evaluating NOUS-209 in combination with anti-PD-1 checkpoint inhibitor (pembrolizumab). The data, presented yesterday in a poster discussion session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated NOUS-209 to be safe, highly immunogenic and with promising signs of clinical efficacy.

Key Points: 
  • NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: "These new data with all patients enrolled continues to reinforce our compelling and differentiating data for NOUS-209.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
星期一, 六月 6, 2022
SD, Oncology, Immunotherapy, Veteran, FSP, GE, US, Society, Modified vaccinia Ankara, AACR, Neoplasm, LinkedIn, MVA, ASCO, Hope, Annual general meeting, Primary health centre, Pembrolizumab, City, American Association, MSI, American Society of Clinical Oncology, MSI-H, Patient, GENESIS, Gad, FDA, DNA, Tumor microenvironment, Trial of the century, Microsatellite instability, Association, Cancer, ELISpot, American Association for Cancer Research, Peptide, Safety, Vaccine, Pharmaceutical industry, Medical imaging

BASEL, Switzerland, June 6, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced first data from the completed Phase 1 trial evaluating NOUS-209 in combination with anti-PD-1 checkpoint inhibitor (pembrolizumab). The data, presented yesterday in a poster discussion session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated NOUS-209 to be safe, highly immunogenic and with promising signs of clinical efficacy.

Key Points: 
  • NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: "These new data with all patients enrolled continues to reinforce our compelling and differentiating data for NOUS-209.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
星期五, 五月 27, 2022
DNA, Immunotherapy, Cancer, Neoplasm, Annual general meeting, Modified vaccinia Ankara, AACR, Gad, MSI, SITC, US, FSP, Society, American Society of Clinical Oncology, Trial of the century, Veteran, FDA, Pembrolizumab, Peptide, Safety, ASCO, GE, LinkedIn, MVA, GENESIS, MSI-H, Primary health centre, Pharmaceutical industry, Vaccine

ASCO will be held virtually and in person in Chicago from 3 to 7th June.

Key Points: 
  • ASCO will be held virtually and in person in Chicago from 3 to 7th June.
  • Nouscom is a clinical stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer vaccines.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/